BioSpace News Archive

Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster and oral presentations at the 16th Annual Global Cardiovascular Clinical Trialist’s Forum (CVCT) in Washington, D.C.

Meeting Highlights Include New Phase 3 Data for EPIDIOLEX in Tuberous Sclerosis Complex and Award-Winning Virtual Reality Experience

Company seeks swine producers to run commercial trials

An estimated 3.6 million Americans miss or delay medical care each year because of transportation issues, according to an analysis by the Transportation Research Board of the National Academy of Sciences.

Fostemsavir is being developed for use in combination with other antiretroviral agents in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to form a suppressive regimen due to resistance, intolerance or safety considerations.

Survey Results Highlight Continuing Strength of US Sector Along with Advances by Emerging Market Competitors

Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it has secured from key shareholders a voluntary extension to lock-up agreements representing approximately 8 million subordinate voting shares, including subordinate voting shares issuable upon conversion of locked-up proportionate voting shares.

The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.

Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced upcoming presentations at the Innovation in Cardiovascular Interventions (ICI) Meeting in Tel-Aviv, Israel

Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the formation of a Scientific Advisory Board comprised of leaders in the fields of de novo protein design, structural biology and immunology.